ReviewJournal of translational medicine2025
RNA methylation in hepatocellular carcinoma: from metabolic reprogramming and immune escape mechanisms to small molecule inhibitor development.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) is a primary liver malignancy characterized by a high mortality rate and unfavorable prognosis. Altered epigenetic modifications have been closely associated with cancer development and tumor immune escape. RNA methylation is a pervasive epigenetic alteration. N6-methyladenosine (m6A), 5-methylcytosine (m5C), N1-methyladenosine (m1A), N7-methylguanosine (m7G), 3-methylcytidine (m3C), pseudouridine (Ψ), and 2'-O-methylation (Nm) are the main types of RNA methylation. Importantly, abnormal RNA modifications in HCC are key drivers in promoting the translation of oncogenic RNA transcripts. This not only provides cancer cells with a growth-promoting edge but also significantly contributes to tumorigenesis, fueling processes such as uncontrolled cell proliferation, invasion, and metastasis. RNA methylation influences metabolic reprogramming, immune cells, and immunological factors by modulating biological processes like RNA splicing, translation, stability, and translocation. Consequently, RNA methylation is pivotal in modulating biological processes including HCC tumor immunity, proliferation, invasion, and metastasis. This paper systematically examines the mechanisms and functions of these seven types of RNA methylations, offering a thorough overview of their roles and probable mechanisms within the HCC tumor microenvironment and immune system. We seek to offer novel insights and ways to enhance the effectiveness of HCC immunotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.